Sanofi plans to invest at least $20 billion in the United States through 2030 to boost manufacturing and research, joining ...

Sanofi said it will invest at least $20 billion in the US through 2030, joining other pharmaceutical companies boosting their ...

(Reuters) -French drugmaker Sanofi said on Wednesday it plans to invest at least $20 billion in the United States through ...

Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job ...

Sanofi (SNY) commits $20B to U.S. research & manufacturing by 2030, boosting R&D & partnerships amidst industry-wide ...

Add Sanofi to the list of drugmakers committing billions to bolster their operations in the United States as President Donald ...

Sanofi India's EBITDA rose 25% to ₹171.9 crore in Q4, with margins improving to 32.1%. Shares closed 2.3% higher at ₹6,066.55 ...

Slow progress, pipeline uncertainty & lack of catalysts weigh despite strong cash. Click to read why KYMR stock is a Hold.

The latest health news highlights Sanofi's $20 billion U.S. investment through 2030, Merck's cancer drug expansion and the ...

The American Academy of Pediatrics has said childhood vaccines are carefully studied in randomized controlled trials — ...

Food allergy in children with atopic dermatitis is associated with an increased risk for asthma, allergic rhinitis, and ...

The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterized by ...